Credits Available: 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC

Description: Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies.

With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination.

This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care.

Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Nurse, Physician Associate/Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Karolina Faysman

UCLA Department of Hematological Malignancies and Cellular therapy
Lead Nurse Practitioner

Karolina Faysman obtained her BSN in California State University, Los Angeles in June of 1999 and began her career in oncology In June of 1999 at the UCLA Department of Hematological Malignancies and Cellular Therapy. She then went on to obtain a degree in Advance Oncology Practice in 2002 from University of California, Los Angeles. Her residency was at UCLA Department of hematological malignancies and cellular therapy. In October of 2002, she accepted a position of a lead Nurse Practitioner in the same department where she continued to practice up to currently.

She is presently pursuing a Doctorate in Clinical Practice at Azusa Pacific University. Her topic of research is minimal residual profile in acute leukemia.

Karolina Faysman is certified in Advance Oncology Practice and is an active member of Advance Hematological Oncology Society. She has been a national speaker since 2006 and had spoken in multiple national conferences and other educational programs. She participated and continues to participate in multiple clinical trials. Her main clinical topics of interests include acute leukemia, aggressive lymphoma, graft versus host disease and myeloma